• Login
    • Join
  • FOLLOW:
  • Subscribe Free
    • Magazine
    • eNewsletter
    Checkout
    • Magazine
    • News
    • Exclusives
    • Nutraceuticals
    • Markets
    • Health
    • Jobs
    • Events
    • Buyers' Guide
    • Showcases
    • More
  • Magazine
  • News
  • Exclusives
  • Nutraceuticals
  • Markets
  • Health
  • Jobs
  • Events
  • Buyers' Guide
  • Showcases
  • Current & Past Issues
    Features
    Columns
    Editorials
    Digital Edition
    Subscribe Now
    Advertise Now
    eNewsletter
    Editorial Guidelines
    Top Features
    Nutraceuticals for Men: Muscle Health and Performance Nutrition

    Aging in Place: Healthy Lifestyles Supplement Science-Based Solutions

    Getting an Edge in Esports: Meeting the Health Needs of Competitive Gamers

    Beyond CBD: Cannabis Compounds Warrant Recognition and More Research

    Leveling Out the Energy Segment for Mainstream, and Rethinking Caffeine
    Breaking News
    Certifications, Approvals and Patents
    Exclusives
    Industry & Market News
    People
    Products
    Regulatory
    Research
    Supplier News
    Supplier Insights
    Live From Shows
    Top News
    Thorne Relaunches Gut Health Test with Microbiome Wipe

    Alkemist Labs Announces Alkemist Assured Seal and Next Generation Transparency Reports

    GC Rieber Foundations Expand Philanthropic Efforts

    Danone Celebrates 10th anniversary of Grant Program for Probiotics Research

    Stratum Nutrition’s Patent Portfolio Grows to Europe and Canada
    Exclusives
    Blogs & Guest Articles
    Health E-Insights
    Area Code 420
    eBook
    Antioxidants
    Dairy-Based Ingredients
    Enzymes
    Fatty Acids
    Fiber & Carbohydrates
    Green Foods
    Herbs & Botanicals
    Marine Nutraceuticals
    Minerals
    Omega 3s
    Probiotics & Prebiotics
    Proteins, Peptides, Amino Acids
    Sweeteners
    Vitamins

    GC Rieber Foundations Expand Philanthropic Efforts

    Danone Celebrates 10th anniversary of Grant Program for Probiotics Research

    Botanical Ingredient MorActive Evidenced to Relieve Back Discomfort

    Cargill’s Stevia Sustainability Program Benchmarked by FSA

    GOED Creates Infographic Highlighting Omega-3 Health Claims Approved in Europe
    Consumer Trends
    Contract Manufacturing
    Cosmeceuticals / Nutricosmetics
    Delivery & Dosage Technologies
    Dietary Supplements
    Flavors & Colors
    Functional Foods & Beverages
    Healthcare Trends
    Medical Nutrition
    Mergers & Acquisitions
    Natural/Organic
    Nutrition Bars
    Packaging
    Pet Nutraceuticals
    Quality & Safety
    Regulations
    Research
    Testing
    World Markets

    Thorne Relaunches Gut Health Test with Microbiome Wipe

    Alkemist Labs Announces Alkemist Assured Seal and Next Generation Transparency Reports

    GC Rieber Foundations Expand Philanthropic Efforts

    Danone Celebrates 10th anniversary of Grant Program for Probiotics Research

    Stratum Nutrition’s Patent Portfolio Grows to Europe and Canada
    Bone & Joint Health
    Cancer Risk
    Cardiovascular Health
    Cognitive Function
    Diabetes & Blood Sugar Management
    Digestive Health
    Energy
    Eye Health
    Healthy Aging
    Immune Function
    Infant & Children's Health
    Inflammation
    Men's Health
    Mood Health & Sleep
    Oral Health
    Sexual & Reproductive Health
    Skin Health
    Sports Nutrition
    Weight Management/Weight Loss
    Women's Health

    Thorne Relaunches Gut Health Test with Microbiome Wipe

    Danone Celebrates 10th anniversary of Grant Program for Probiotics Research

    Beyond Raw Launches Concept X Pre-Workout Line

    Botanical Ingredient MorActive Evidenced to Relieve Back Discomfort

    Kyowa Hakko Appoints Dr. Colin Hill to Immuse Scientific Advisory Board
    Industry Events
    Live From Show Events
    Webinars
    All Companies
    Categories
    Trade Associations
    Company Capabilities
    International Buyers Guide Companies
    KLK OLEO

    Applied Food Sciences, Inc.

    Aiya America, Inc. (Aiya Matcha)

    Ecuadorian Rainforest

    Nutrition21, LLC
    Companies
    Product Releases
    News Releases
    Literature / Brochures
    White Papers
    Jobs
    VIdeos
    Services
    Add New Company
    International Buyers Guide Companies
    KLK OLEO

    Applied Food Sciences, Inc.

    Aiya America, Inc. (Aiya Matcha)

    Ecuadorian Rainforest

    Nutrition21, LLC
    • Magazine
      • Current / Back Issue
      • Features
      • Editorial
      • Columns
      • Digital Edition
      • eNewsletter Archive
      • Editorial Guidelines
      • Subscribe Now
      • Advertise Now
    • Breaking News
    • Buyers' Guide
      • All Companies
      • Categories
      • Trade Associations
      • Company Capabilities
    • Nutraceuticals
      • Antioxidants
      • Dairy-Based Ingredients
      • Enzymes
      • Fatty Acids
      • Fiber & Carbohydrates
      • Green Foods
      • Herbs & Botanicals
      • Marine Nutraceuticals
      • Minerals
      • Omega 3s
      • Probiotics & Prebiotics
      • Proteins, Peptides, Amino Acids
      • Sweeteners
      • Vitamins
    • Markets
      • Consumer Trends
      • Contract Manufacturing
      • Cosmeceuticals / Nutricosmetics
      • Delivery & Dosage Technologies
      • Dietary Supplements
      • Flavors & Colors
      • Functional Foods & Beverages
      • Healthcare Trends
      • Medical Nutrition
      • Mergers & Acquisitions
      • Natural/Organic
      • Nutrition Bars
      • Packaging
      • Pet Nutraceuticals
      • Quality & Safety
      • Regulations
      • Research
      • Testing
      • World Markets
    • Health
      • Bone & Joint Health
      • Cancer Risk
      • Cardiovascular Health
      • Cognitive Function
      • Diabetes & Blood Sugar Management
      • Digestive Health
      • Energy
      • Eye Health
      • Healthy Aging
      • Immune Function
      • Infant & Children's Health
      • Inflammation
      • Men's Health
      • Mood Health & Sleep
      • Oral Health
      • Sexual & Reproductive Health
      • Skin Health
      • Sports Nutrition
      • Weight Management/Weight Loss
      • Women's Health
    • Online Exclusives
    • Webinars
    • Slideshows
    • Blogs & Guest Articles
    • Health E-Insights
    • Videos
    • Podcasts
    • Infographics
    • eBook
    • Whitepapers
    • Research
      • TrendSense
      • Monograph Center
      • White Papers
      • Research News
    • Jobs
    • Events
      • Industry Events
      • Live From Show Events
      • Webinars
    • Supplier Showcases
      • Companies
      • Product Releases
      • News Releases
      • Literature / Brochures
      • White Papers
      • Jobs
      • VIdeos
      • Services
    • About Us
      • About Us
      • Contact Us
      • Advertise With Us
      • Privacy Policy
      • Terms of Use
    Columns

    The Regulatory Drumbeat Continues to Echo

    FDA’s latest actions exemplify how it views the dietary supplement industry.

    The Regulatory Drumbeat Continues to Echo
    Related CONTENT
    • FDA Issues Draft Guidance on NDI Enforcement Discretion
    • Draft Senate Bill to Reauthorize FDA User Fees Includes Dietary Supplement Listing Provision
    • Open Book Extracts Completes Phase 1 of Toxicology, Safety Assessment for Cannabinoid Ingredients
    • Is There Momentum to Modernize DSHEA, or Too Much Division?
    • NPA Letter Spells Out Perceived Failings of Proposed Dietary Supplement Listing Act
    Todd Harrison, Venable11.01.16
    The dietary supplement industry once again finds itself in the crosshairs of U.S. regulators. In August, FDA issued its revised draft guidance document regarding New Dietary Ingredient (NDI) notifications. Subsequently, the agency has requested comments related to its tentative conclusion that vinpocetine is not a dietary ingredient—regardless of the fact that FDA, on five previous occasions, had the opportunity to raise an issue regarding its regulatory status.

    Meanwhile, the New York Attorney General (AG) reached another settlement with a large dietary supplement company regarding supply chain integrity and DNA testing (NBTY, Inc.). And the Drug Enforcement Agency (DEA) attempted to schedule a benign herb (kratom) through its emergency scheduling process. Additional developments have included recent settlements out of the State Iowa AG office and the state of California.

    What do all of these situations have in common? The constant drumbeat from regulators has been that the industry is simply not doing enough to self-regulate. This overall perception has not changed, quite frankly, since the Dietary Supplement Health and Education Act (DSHEA) was passed in October 1994; but is this all the fault of industry, or do regulators bear responsibility in this process?

    FDA’s Inaction & Ambivalence
    From my perspective, while the industry has not always done its best to comply with the requirements of DSHEA, I would argue that a large part of the blame falls on regulators—FDA in particular. The new NDI draft guidance, the NY AG’s efforts on traceability, DEA’s misstep with kratom, and even the issues surrounding claims can be directly attributable to FDA’s general ambivalence—some would say outright hostility—toward the industry. One only needs to look at the timeline to figure out that many of these issues could have been avoided if FDA would have simply taken a more active approach toward regulating the industry in 1994.

    DSHEA became effective on Oct. 14, 1994; yet during the next 22 years, FDA rarely did anything with regard to supply chain integrity and new dietary ingredients. For instance, it should not take the NY AG to enter into agreements with GNC and NBTY to make it clear that ingredient manufacturers are an integral part of ensuring supply chain integrity.

    Indeed, the issue of identity testing should not start at the finished product manufacturing stage, but rather at the ingredient manufacturing stage. Especially with botanicals, the ingredient manufacturer is in better position to conduct the initial identity testing than the finished product manufacturer. Yet, FDA made a decision to exempt ingredient manufacturers from Part 111. To this day that decision is dumbfounding to me.

    FDA continues to ignore a citizen petition by the Organic & Natural Health Association that requested the agency bring ingredient manufacturers under Part 111, even though state AGs and members of Congress have called for the same. FDA could achieve this task in short order. Instead, the NY AG is making agreements with companies to make this happen; however, these companies by themselves can’t achieve the ultimate goal, as the ingredient manufacturing industry is not of an insignificant size. 

    New Dietary Ingredients
    First, in the immortal words of Green Bay Packers Quarterback Aaron Rodgers: r-e-l-a-x, Relax. The draft guidance is just that—a draft guidance document. Moreover, it only represents FDA’s current thinking on the matter and does not have the effect of law. Forget for a moment that FDA has no ability under the law to reject a notification or to approve new dietary ingredients; as stated in my last column, the document has fundamental issues that the agency still needs to work through (September 2016, “FDA Issues Revised Draft Guidance On New Dietary Ingredients”).

    With that said, if the agency had worked with industry in 1994-1995 on developing a positive list of ingredients, as well as a policy around what would be considered a new dietary ingredient—such as a substantial change in concentration of a particular ingredient—we would not be in a situation today where we need to determine what is rightfully an “old” dietary ingredient.

    Yet, it has taken FDA more than 22 years to determine that it should compile such a list, even though the industry had compiled a list back in the mid-1990s, which FDA has refused to adopt. The agency should start with that list and request information on ingredients that are not on the list. Yet, for whatever reason, FDA is simply rejecting this approach, which is nonsensical and feeds into the general perception that the industry can’t be trusted. FDA has reinforced this perception with vinpocetine. 

    Vinpocetine’s Regulatory Status
    As everyone knows, including FDA, there were no less than five new dietary ingredient notifications regarding vinpocetine without comment from the agency. Yet, even though this ingredient is reasonably expected to be safe, in what appears to be a purely political decision sparked by Senator Claire McCaskill (D-MO), FDA decided to dig up some old press releases regarding this ingredient. 

    The industry has a reason to take issue because FDA has, at a minimum, treated the new dietary ingredient notification as a quasi-approval process—if not an outright approval process—and the industry should have been able to rely on it when making decisions about whether to incorporate a new dietary ingredient into a finished dietary supplement. This is not a situation where an ingredient supplier was relying on a Generally Recognized As Safe (GRAS) self-determination, or use in the food supply to escape the notification process. Rather, the notification was actually filed and FDA had no comment.  “No comment” does not mean FDA agrees with the notice; however, given FDA’s propensity to question these notifications, it is absurd that the agency now has a concern, stating that because it believes vinpocetine is a synthetic ingredient, subject of an investigational new drug (IND) application and substantial, public clinical trials in the U.S. prior to its introduction as a dietary ingredient. 

    Putting aside the latter point, which poses significant issues, there is simply not justification for FDA’s position on synthetic botanicals or ingredients synthesized from botanicals. Nowhere in DSHEA or its legislative history does it indicate that synthetics are not permitted. Indeed, the catch-all provision of DSHEA regarding a “dietary substance” when viewed in light of the “new” dietary ingredient notification provisions clearly contemplates that new dietary substances would be developed. Otherwise, the new dietary ingredient notification provision would rarely be used, which was not the intent of Congress. 

    Moreover, the use of the term “substance,” rather than nutrient or nutritive, clearly indicates that Congress contemplated something other than one of the specific categories delineated in the definition of a dietary supplement. In other words, “substance” contemplates synthetic ingredients that may be developed. Thus, FDA’s position on synthetic botanicals is directly at odds with Congressional intent.

    Regardless, if we are going to treat the notification process as just that—a notification process—it is difficult to penalize the agency for not understanding that an IND and substantial, public clinical trials were conducted on an ingredient. 

    Moreover, it should be required for the notifier to certify that the ingredient was not the subject of the IND and clinical trials prior to the submission of the notification. With that said, FDA is treating this requirement as an absolute bar. However, that is simply not true. More specifically, FDA has the authority to permit its use as a dietary supplement if after notice and comment the agency finds the article can be lawfully marketed as a dietary supplement. (See Federal Food, Drug, and Cosmetic Act § 201(ff)(3)(B)(ii).)  

    Of particular importance in this instance, if the drug approval had already taken place under §201(ff)(3)(A), this option would not be available. In other words, Congress recognized that there may be instances where a substance is not approved because it did not help in the treatment of a disease but would have value to overall health and well-being as a dietary substance. Accordingly, we would hope FDA understands this important distinction and use its request for comments on vinpocetine to affirm its use as a dietary ingredient; there is no question that it has never been approved as a drug in the U.S., and it has a reasonable expectation of safety based on FDA’s own review.

    As an industry, we do need to do better. However, FDA needs to step up and understand that we cannot simply hit a reset button that suddenly sends us back to October 1994. FDA should affirm vinpocetine’s use as a dietary ingredient as permitted under the FFD&C Act, abandon its view on synthetics and bring ingredient manufacturers under Part 111.


    Todd Harrison
    Venable

    Todd Harrison is partner with Venable, which is located in Washington, D.C. He advises food and drug companies on a variety of FDA and FTC matters, with an emphasis on dietary supplement, functional food, biotech, legislative, adulteration, labeling and advertising issues. He can be reached at 575 7th St. NW, Washington, D.C. 20004, Tel: 202-344-4724; E-mail: taharrison@venable.com.
    Related Searches
    • Regulations
    • Quality & Safety
    • Testing
    • Dietary Supplements
    Related Knowledge Center
    • Regulations
    • Dietary Supplements
    • Testing
    Suggested For You
    FDA Issues Draft Guidance on NDI Enforcement Discretion FDA Issues Draft Guidance on NDI Enforcement Discretion
    Draft Senate Bill to Reauthorize FDA User Fees Includes Dietary Supplement Listing Provision Draft Senate Bill to Reauthorize FDA User Fees Includes Dietary Supplement Listing Provision
    Open Book Extracts Completes Phase 1 of Toxicology, Safety Assessment for Cannabinoid Ingredients Open Book Extracts Completes Phase 1 of Toxicology, Safety Assessment for Cannabinoid Ingredients
    Is There Momentum to Modernize DSHEA, or Too Much Division? Is There Momentum to Modernize DSHEA, or Too Much Division?
    NPA Letter Spells Out Perceived Failings of Proposed Dietary Supplement Listing Act NPA Letter Spells Out Perceived Failings of Proposed Dietary Supplement Listing Act
    Dietary Supplement Listing Bill Introduced in Senate Dietary Supplement Listing Bill Introduced in Senate
    Nuseed’s Omega-3 Canola Ingredients Succeed FDA Review For Human, Animal Safety Nuseed’s Omega-3 Canola Ingredients Succeed FDA Review For Human, Animal Safety
    The Nuts and Bolts of FDA’s 2023 Budget Request The Nuts and Bolts of FDA’s 2023 Budget Request
    Hemp and CBD Updates: Industry Still in the Weeds Hemp and CBD Updates: Industry Still in the Weeds
    NAC Supplements Could be Banned Unless FDA Reverses Course NAC Supplements Could be Banned Unless FDA Reverses Course
    NPA Citizen’s Petition Asks FDA to Declare CBD as Lawful Dietary Ingredient NPA Citizen’s Petition Asks FDA to Declare CBD as Lawful Dietary Ingredient
    DSM Gains New Dietary Ingredient Status for Two Probiotic Strains in U.S. DSM Gains New Dietary Ingredient Status for Two Probiotic Strains in U.S.
    Top Articles From Nutraceuticals World in 2021 Top Articles From Nutraceuticals World in 2021
    Understanding Exclusion (Preclusion) and a Proposed Solution Understanding Exclusion (Preclusion) and a Proposed Solution
    Claims Spell Success in Today’s Nutritional Products Market Claims Spell Success in Today’s Nutritional Products Market

    Related Content

    • Dietary Supplements | Regulations
      FDA Issues Draft Guidance on NDI Enforcement Discretion

      FDA Issues Draft Guidance on NDI Enforcement Discretion

      Amnesty for late NDI notifications is intended to encourage manufacturers and distributors to correct past failures while collecting safety data, FDA said.
      By Sean Moloughney, Editor 05.20.22

    • Dietary Supplements | Regulations
      Draft Senate Bill to Reauthorize FDA User Fees Includes Dietary Supplement Listing Provision

      Draft Senate Bill to Reauthorize FDA User Fees Includes Dietary Supplement Listing Provision

      HELP Committee released discussion draft that includes language similar to Senate Bill 4090 introduced last month by Senators Durbin and Braun.
      By Sean Moloughney, Editor 05.18.22

    • Herbs & Botanicals | Quality & Safety | Testing
      Open Book Extracts Completes Phase 1 of Toxicology, Safety Assessment for Cannabinoid Ingredients

      Open Book Extracts Completes Phase 1 of Toxicology, Safety Assessment for Cannabinoid Ingredients

      The report concluded CBG, CBN, and CBC test articles were non-mutagenic, non-clastogenic, and non-genotoxic.
      05.06.22


    • Dietary Supplements | Regulations
      Is There Momentum to Modernize DSHEA, or Too Much Division?

      Is There Momentum to Modernize DSHEA, or Too Much Division?

      Senate Bill 4090 would require supplement manufacturers to list products with FDA prior to entering commerce.
      By Sean Moloughney, Editor 05.03.22

    • Dietary Supplements | Regulations
      NPA Letter Spells Out Perceived Failings of Proposed Dietary Supplement Listing Act

      NPA Letter Spells Out Perceived Failings of Proposed Dietary Supplement Listing Act

      Daniel Fabricant, NPA president and CEO, lays out ‘grave concerns’ with mandatory product listing bill in message to Sens. Durbin and Braun.
      By Mike Montemarano, Associate Editor 04.29.22

      Trending
      • Leaven Essential To Launch Branded Botanical Extracts To Global Markets | Nutraceuticals World
      • Oregon Files Lawsuit Against GNC | Nutraceuticals World
      • Vitamin D3, Omega-3s, Exercise May Cumulatively Reduce Cancer Risk In Older Adults | Nutraceuticals World
      • Coca-Cola To Phase Out Honest Tea Brand By Year’s End, Citing Supply Chain Challenges | Nutraceuticals World
      Breaking News
      • Thorne Relaunches Gut Health Test with Microbiome Wipe
      • Alkemist Labs Announces Alkemist Assured Seal and Next Generation Transparency Reports
      • GC Rieber Foundations Expand Philanthropic Efforts
      • Danone Celebrates 10th anniversary of Grant Program for Probiotics Research
      • Stratum Nutrition’s Patent Portfolio Grows to Europe and Canada
      View Breaking News >
      CURRENT ISSUE

      May 2022

      • Aging in Place: Lifestyle Supplements Science-Based Solutions
      • Getting an Edge in Esports: Meeting Health & Nutrition Needs
      • Nutraceuticals for Men: Muscle Health and Performance Nutrition

      Cookies help us to provide you with an excellent service. By using our website, you declare yourself in agreement with our use of cookies.
      You can obtain detailed information about the use of cookies on our website by clicking on "More information”.

      • About Us
      • Privacy Policy
      • Terms And Conditions
      • Contact Us

      follow us

      Subscribe
      Nutraceuticals World

      Latest Breaking News From Nutraceuticals World

      Thorne Relaunches Gut Health Test with Microbiome Wipe
      Alkemist Labs Announces Alkemist Assured Seal and Next Generation Transparency Reports
      GC Rieber Foundations Expand Philanthropic Efforts
      Coatings World

      Latest Breaking News From Coatings World

      PPG Hosts The Future of Coatings' Technology Innovation Day in Amsterdam
      Azelis Expands Presence in India with Acquisition of Chemo India and Unipharm Laboratories
      Teknos Publishes Sustainability Report
      Medical Product Outsourcing

      Latest Breaking News From Medical Product Outsourcing

      Pediatric Medical Device Competition Reveals Five Finalists
      Medical Device Packaging Market to Reach $34B by 2027
      Penumbra Secures CE Mark for its Advanced Mechanical Thrombectomy Tech
      Contract Pharma

      Latest Breaking News From Contract Pharma

      Mirum Pharmaceuticals Acquires San Diego-based Satiogen
      Catalyst Biosciences Sells Complement Portfolio to Vertex Pharmaceuticals
      Insmed Appoints Drayton Wise as Chief Commercial Officer
      Beauty Packaging

      Latest Breaking News From Beauty Packaging

      La Roche-Posay Launches Matte Moisturizer for Oily Skin
      3 Amorepacific Employees Stole $2.3 Million
      L'Oreal CEO Nicolas Hieronimus On Sustainability Initiatives
      Happi

      Latest Breaking News From Happi

      Thayers Natural Remedies Celebrates 175 Years with Social Campaign
      Former Model Shirley Powell’s Indie Beauty Brand LaJeanell Comprises Gender Inclusive Skincare and Makeup
      L’Oréal's New UVMune 400 Sun Filtering Technology Protects Skin From Ultra-Long UVA Rays
      Ink World

      Latest Breaking News From Ink World

      Flint Group Flexible Packaging Europe Implements Further Price Increase
      Nazdar Launches 205 Series Inks for Roland TrueVIS SG2 and VG2 Series Printers
      Quad Adds Landa S10P Nanographic Printing Press
      Label & Narrow Web

      Latest Breaking News From Label & Narrow Web

      AWA to host 22nd Global Release Liner Industry Conference & Exhibition
      Domino assists Grace Label with supply chain disruptions
      Rotocon wins AI Business Excellence Award
      Nonwovens Industry

      Latest Breaking News From Nonwovens Industry

      Rael Raises $35M in Series B Funding
      Schobertechnologies Offers Rotary Web-fed Converting Solutions
      Thorne Relaunches Gut Health Test with Microbiome Wipe
      Orthopedic Design & Technology

      Latest Breaking News From Orthopedic Design & Technology

      Study Confirms Knee Shapes are Highly Individualized
      Stryker Launches EasyFuse Dynamic Compression for Foot & Ankle
      Extremity Medical Rolls Out OMNI Stable Ankle Fracture System
      Printed Electronics Now

      Latest Breaking News From Printed Electronics Now

      InnovationLab Acquires Flexible Printed Battery Technology from Evonik
      Canatu Receives IATF 16949:2016 Certification
      Applied Materials Announces 2Q 2022 Results

      Copyright © 2022 Rodman Media. All rights reserved. Use of this constitutes acceptance of our privacy policy The material on this site may not be reproduced, distributed, transmitted, or otherwise used, except with the prior written permission of Rodman Media.

      AD BLOCKER DETECTED

      Our website is made possible by displaying online advertisements to our visitors.
      Please consider supporting us by disabling your ad blocker.


      FREE SUBSCRIPTION Already a subscriber? Login